Search hospitals > Georgia > Columbus
John B. Amos Cancer Center
Claim this profileColumbus, Georgia 31904
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Breast cancer
Conducts research for Brain Tumor
209 reported clinical trials
1 medical researcher
Summary
John B. Amos Cancer Center is a medical facility located in Columbus, Georgia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Breast cancer, Brain Tumor and other specialties. John B. Amos Cancer Center is involved with conducting 209 clinical trials across 328 conditions. There are 1 research doctors associated with this hospital, such as Andrew W. Pippas.Area of expertise
1Breast Cancer
Global LeaderER positive
PR positive
HER2 negative
2Lung Cancer
Global LeaderStage III
Stage I
Stage II
Top PIs
Clinical Trials running at John B. Amos Cancer Center
Lung Cancer
Colorectal Cancer
Small Cell Lung Cancer
Cancer
Pancreatic Cancer
Breast cancer
Melanoma
ALK Gene Rearrangement
Cardiotoxicity
Sarcopenia
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
Cancer Cachexia
for Colorectal, Lung, and Pancreatic Cancer
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.
Recruiting1 award N/A7 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at John B. Amos Cancer Center?
John B. Amos Cancer Center is a medical facility located in Columbus, Georgia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Breast cancer, Brain Tumor and other specialties. John B. Amos Cancer Center is involved with conducting 209 clinical trials across 328 conditions. There are 1 research doctors associated with this hospital, such as Andrew W. Pippas.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.